Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Core Insights - Enlivex Therapeutics is presenting two poster abstracts at the OARSI 2025 World Congress, focusing on Allocetra™ as a novel therapeutic approach for osteoarthritis [1][2] - The company emphasizes the potential of Allocetra™ to restore macrophage homeostasis, addressing chronic joint inflammation and cartilage degradation [2] Company Overview - Enlivex Therapeutics is a clinical-stage company specializing in macrophage reprogramming immunotherapy, developing Allocetra™, an off-the-shelf cell therapy aimed at reprogramming macrophages to a homeostatic state [7] - The company believes that resetting non-homeostatic macrophages is crucial for immune system rebalancing and resolving debilitating conditions [7] Clinical Data - Allocetra™ has shown favorable safety and promising efficacy in Phase I/II studies for moderate and end-stage osteoarthritis, including significant pain reduction and improved joint function [3] - The therapy has demonstrated the potential to avoid knee replacement surgery, supported by preclinical studies on its mechanism of action in modulating macrophage-driven inflammation [3] Conference Details - The presentations at OARSI 2025 will include data from both preclinical and clinical studies evaluating Allocetra™ in osteoarthritis patients [2] - Specific sessions include a Flash Talk on April 26, 2025, and poster sessions on April 25 and 26, 2025, showcasing the biological activity of Allocetra™ [8]